↓ Skip to main content

Dove Medical Press

Article Metrics

Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery

Overview of attention for article published in International Journal of Nanomedicine, August 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

twitter
3 tweeters
patent
1 patent
googleplus
1 Google+ user

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
50 Mendeley
Title
Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery
Published in
International Journal of Nanomedicine, August 2015
DOI 10.2147/ijn.s87145
Pubmed ID
Authors

Young-Il Jeong, Hyung-Kyu Park, Sang Joon Lee, Jong-Suk Oh, Sam-Gyu Lee, Hyun Chul Lee, Dae Hwan Kang

Abstract

Since cancer cells are normally over-expressed cathepsin B, we synthesized dendrimer-methoxy poly(ethylene glycol) (MPEG)-doxorubicin (DOX) conjugates using a cathepsin B-cleavable peptide for anticancer drug targeting. Gly-Phe-Leu-Gly peptide was conjugated with the carboxylic acid end groups of a dendrimer, which was then conjugated with MPEG amine and doxorubicin by aid of carbodiimide chemistry (abbreviated as DendGDP). Dendrimer-MPEG-DOX conjugates without Gly-Phe-Leu-Gly peptide linkage was also synthesized for comparison (DendDP). Nanoparticles were then prepared using a dialysis procedure. The synthesized DendGDP was confirmed with (1)H nuclear magnetic resonance spectroscopy. The DendDP and DendGDP nanoparticles had a small particle size of less than 200 nm and had a spherical morphology. DendGDP had cathepsin B-sensitive drug release properties while DendDP did not show cathepsin B sensitivity. Further, DendGDP had improved anticancer activity when compared with doxorubicin or DendDP in an in vivo CT26 tumor xenograft model, ie, the volume of the CT26 tumor xenograft was significantly inhibited when compared with xenografts treated with doxorubicin or DendDP nanoparticles. The DendGDP nanoparticles were found to be relatively concentrated in the tumor tissue and revealed stronger fluorescence intensity than at other body sites while doxorubicin and DendDP nanoparticles showed strong fluorescence intensity in the various organs, indicating that DendGDP has cathepsin B sensitivity. DendGDP is sensitive to cathepsin B in tumor cells and can be used as a cathepsin B-responsive drug targeting strategy. We suggest that DendGDP is a promising vehicle for cancer cell targeting.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 50 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 24%
Student > Master 8 16%
Student > Postgraduate 5 10%
Student > Bachelor 5 10%
Student > Doctoral Student 4 8%
Other 8 16%
Unknown 8 16%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 10 20%
Chemistry 7 14%
Biochemistry, Genetics and Molecular Biology 6 12%
Medicine and Dentistry 4 8%
Agricultural and Biological Sciences 3 6%
Other 7 14%
Unknown 13 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2020.
All research outputs
#4,285,536
of 17,379,776 outputs
Outputs from International Journal of Nanomedicine
#357
of 3,179 outputs
Outputs of similar age
#58,099
of 245,060 outputs
Outputs of similar age from International Journal of Nanomedicine
#6
of 148 outputs
Altmetric has tracked 17,379,776 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,179 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 245,060 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 148 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.